MX346115B - Metodo para mejorar la eliminación de virus en la purificacion proteica. - Google Patents

Metodo para mejorar la eliminación de virus en la purificacion proteica.

Info

Publication number
MX346115B
MX346115B MX2012001659A MX2012001659A MX346115B MX 346115 B MX346115 B MX 346115B MX 2012001659 A MX2012001659 A MX 2012001659A MX 2012001659 A MX2012001659 A MX 2012001659A MX 346115 B MX346115 B MX 346115B
Authority
MX
Mexico
Prior art keywords
viruses
elimination
improve
proteic purification
relates
Prior art date
Application number
MX2012001659A
Other languages
English (en)
Other versions
MX2012001659A (es
Inventor
Mehta Amit
Original Assignee
Genentech Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346115(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc * filed Critical Genentech Inc *
Publication of MX2012001659A publication Critical patent/MX2012001659A/es
Publication of MX346115B publication Critical patent/MX346115B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere al campo de la purificación proteica. En particular, la invención se refiere a métodos para aumentar la capacidad de filtración de filtros de virus mediante el uso combinado de medios de eliminación de endotoxinas e intercambio catiónico en el proceso de prefiltración.
MX2012001659A 2009-08-06 2010-08-06 Metodo para mejorar la eliminación de virus en la purificacion proteica. MX346115B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23181109P 2009-08-06 2009-08-06
PCT/US2010/044760 WO2011031397A1 (en) 2009-08-06 2010-08-06 Method to improve virus removal in protein purification

Publications (2)

Publication Number Publication Date
MX2012001659A MX2012001659A (es) 2012-04-30
MX346115B true MX346115B (es) 2017-03-08

Family

ID=42985499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001659A MX346115B (es) 2009-08-06 2010-08-06 Metodo para mejorar la eliminación de virus en la purificacion proteica.

Country Status (25)

Country Link
US (5) US10662237B2 (es)
EP (3) EP4559926A3 (es)
JP (6) JP2013501075A (es)
KR (3) KR20190018041A (es)
CN (2) CN106905413A (es)
AU (1) AU2010292897B2 (es)
BR (1) BR112012002574A2 (es)
CA (1) CA2770235C (es)
DK (1) DK2462158T3 (es)
ES (1) ES2662529T3 (es)
HR (1) HRP20180309T1 (es)
HU (1) HUE038451T2 (es)
IL (3) IL217740B (es)
LT (1) LT2462158T (es)
MX (1) MX346115B (es)
MY (1) MY188566A (es)
NO (1) NO2462158T3 (es)
NZ (1) NZ597809A (es)
PL (1) PL2462158T3 (es)
PT (1) PT2462158T (es)
RU (1) RU2573894C2 (es)
SG (1) SG178276A1 (es)
SI (1) SI2462158T1 (es)
WO (1) WO2011031397A1 (es)
ZA (1) ZA201200626B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2010048192A2 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
RU2520838C2 (ru) 2008-10-20 2014-06-27 Эббви Инк Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
AU2010292897B2 (en) 2009-08-06 2016-01-07 Genentech, Inc. Method to improve virus removal in protein purification
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP2697369B1 (en) * 2011-03-25 2018-06-27 F.Hoffmann-La Roche Ag Novel protein purification methods
DE102011105525B4 (de) 2011-06-24 2015-03-26 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Biopolymer-Aggregaten und Viren aus einem Fluid
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
WO2015038884A2 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
IL320195A (en) 2013-09-13 2025-06-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
EP3209767B1 (en) * 2014-10-21 2020-08-05 Gennova Biopharmaceuticals Ltd. A novel purification process for isolation and commercial production of recombinant tnk-tpa (tenecteplase)
WO2016154290A1 (en) * 2015-03-23 2016-09-29 Alexion Pharmaceuticals, Inc. Virus filtration
CA3066062C (en) * 2017-06-12 2023-02-14 Asahi Kasei Medical Co., Ltd. Method for filtering protein-containing liquid
IL311002A (en) * 2017-12-21 2024-04-01 Genzyme Corp Methods for improved removal of impurities during protein A chromatography
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE108068T1 (de) 1987-09-23 1994-07-15 Bristol Myers Squibb Co Antikörper-heterokonjugate zur töting von hiv- infizierten zellen.
WO1989005859A1 (en) 1987-12-21 1989-06-29 The Upjohn Company Agrobacterium mediated transformation of germinating plant seeds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JPH02198687A (ja) 1989-01-26 1990-08-07 Asahi Chem Ind Co Ltd 純水の製造方法
JPH038759A (ja) 1989-03-16 1991-01-16 Sumitomo Metal Ind Ltd 半導体磁器物質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
ATE213639T1 (de) * 1993-07-09 2002-03-15 Avant Immunotherapeutics Inc Proteinreinigung
CA2106612C (en) 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
RU2145873C1 (ru) 1993-09-21 2000-02-27 Хемосол Инк. Способ очистки гемоглобина в коммерческом масштабе
JP3415222B2 (ja) 1993-10-20 2003-06-09 東洋濾紙株式会社 エンドトキシン吸着能を有するポリエーテルサルホン又はスルホン化ポリエーテルサルホン微孔膜
JP3453623B2 (ja) 1994-03-30 2003-10-06 サンスター株式会社 エンドトキシン吸着除去剤および除去方法
WO1996003202A1 (en) 1994-07-28 1996-02-08 Millipore Corporation Porous composite membrane and process
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
DE59709915D1 (de) 1996-02-06 2003-05-28 Roche Diagnostics Gmbh Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung
TW505655B (en) 1997-10-14 2002-10-11 Tanox Inc Enhanced aggregate removal from bulk-biologicals using ion exchange chromatography
GB9907553D0 (en) * 1999-04-01 1999-05-26 Cantab Pharma Res Purification of biological preparations
AU778022B2 (en) 1999-07-30 2004-11-11 Genentech Inc. Charged filtration membranes and uses therefor
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7118675B2 (en) * 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
NZ539297A (en) 2002-09-13 2008-04-30 Biogen Idec Inc Method of purifying polypeptides by simulated moving bed chromatography
EP1403274A1 (en) 2002-09-30 2004-03-31 Meristem Therapeutics Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
US20040116676A1 (en) 2002-09-30 2004-06-17 Hotta Joann Methods for removal of contaminants from blood product solutions
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
US20060257972A1 (en) 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
IN2009KN02655A (es) * 2003-12-10 2015-10-23 Medarex Inc
EP1709077A1 (en) 2004-01-30 2006-10-11 Suomen Punainen Risti Veripalvelu Process for the manufacture of virus safe immunoglobulin
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
US7390403B2 (en) 2004-03-19 2008-06-24 Millipore Corporation Prefilter system for biological systems
WO2006042541A1 (en) 2004-10-21 2006-04-27 Statens Serum Institut A method comprising nanofiltration to obtain an mbl product safe from infectious agents and the product obtainable by this method
JP2006249082A (ja) * 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 低減レベルの内毒素を有する抗ｍ−ｃｓｆ抗体組成物
CN101437839A (zh) * 2006-03-20 2009-05-20 米德列斯公司 蛋白质纯化
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
WO2009017491A1 (en) * 2006-06-14 2009-02-05 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
EP2061802A1 (en) 2006-08-28 2009-05-27 Ares Trading S.A. Process for the purification of fc-fusion proteins
US20080132688A1 (en) 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
RU2460541C2 (ru) 2006-10-27 2012-09-10 Лпат, Инк. Композиции и способы связывания сфингозин-1-фосфата
US20080207487A1 (en) 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
AU2007323978B2 (en) 2006-11-08 2012-08-16 Wyeth Llc Rationally designed media for cell culture
CN105567627B (zh) 2007-04-26 2020-09-29 中外制药株式会社 使用含高浓度氨基酸的培养基的细胞培养方法
CN101945890A (zh) 2007-12-21 2011-01-12 健泰科生物技术公司 抗cd20抗体的结晶
WO2009138484A2 (en) 2008-05-15 2009-11-19 Novo Nordisk A/S Antibody purification process
ES2573663T5 (es) * 2009-03-27 2019-12-12 Asahi Kasei Medical Co Ltd Procedimiento para eliminar virus de una solución de anticuerpos monoclonales de concentración elevada
EP2762492A3 (en) 2009-05-27 2015-03-18 Baxter International Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010292897B2 (en) 2009-08-06 2016-01-07 Genentech, Inc. Method to improve virus removal in protein purification
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution

Also Published As

Publication number Publication date
IL273486B (en) 2022-04-01
EP4559926A2 (en) 2025-05-28
SI2462158T1 (en) 2018-04-30
IL273486A (en) 2020-05-31
MX2012001659A (es) 2012-04-30
IL217740B (en) 2020-04-30
AU2010292897B2 (en) 2016-01-07
JP2023029853A (ja) 2023-03-07
JP2016106096A (ja) 2016-06-16
US20110034674A1 (en) 2011-02-10
LT2462158T (lt) 2018-03-26
US10662237B2 (en) 2020-05-26
EP4559926A3 (en) 2025-08-06
EP2462158B1 (en) 2018-01-10
ZA201200626B (en) 2013-06-26
CN102712691A (zh) 2012-10-03
KR20190018041A (ko) 2019-02-20
US11225513B2 (en) 2022-01-18
NO2462158T3 (es) 2018-06-09
US20200347118A1 (en) 2020-11-05
HRP20180309T1 (hr) 2018-03-23
CA2770235C (en) 2021-06-29
ES2662529T3 (es) 2018-04-06
PT2462158T (pt) 2018-02-23
NZ597809A (en) 2014-05-30
WO2011031397A1 (en) 2011-03-17
KR20130051431A (ko) 2013-05-20
RU2012108318A (ru) 2013-09-20
JP2013501075A (ja) 2013-01-10
DK2462158T3 (en) 2018-03-05
HUE038451T2 (hu) 2018-10-29
US20220306726A1 (en) 2022-09-29
SG178276A1 (en) 2012-03-29
KR20180035936A (ko) 2018-04-06
CN106905413A (zh) 2017-06-30
IL217740A0 (en) 2012-03-29
JP2020023491A (ja) 2020-02-13
RU2573894C2 (ru) 2016-01-27
BR112012002574A2 (pt) 2020-11-03
JP2017206529A (ja) 2017-11-24
AU2010292897A1 (en) 2012-02-16
PL2462158T3 (pl) 2018-05-30
EP3309168A1 (en) 2018-04-18
MY188566A (en) 2021-12-22
KR101844859B1 (ko) 2018-05-18
US20240083980A1 (en) 2024-03-14
CA2770235A1 (en) 2011-03-17
US20250282850A1 (en) 2025-09-11
EP2462158A1 (en) 2012-06-13
JP2025003999A (ja) 2025-01-14
IL287431A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MX346115B (es) Metodo para mejorar la eliminación de virus en la purificacion proteica.
EA201990887A1 (ru) Вирусная фильтрация сред клеточных культур
MX2020004603A (es) Metodos de purificacion de arn mensajero.
AR091538A1 (es) Purificacion de particulas tipo virus
MX2013010737A (es) Novedosos metodos de purificacion de proteinas.
MX2021009891A (es) Metodos para purificar polisacaridos bacterianos.
EA201591229A1 (ru) Способы очистки матричной рнк
MX349601B (es) Remocion de virus contaminantes de preparaciones de aav.
EA201070987A1 (ru) Очищенные гибридные белки иммуноглобулина и способы их очищения
EA201391166A1 (ru) Способ и система обработки воды, используемой для промышленных целей
MX392274B (es) Cartuchos utiles en limpieza de soluciones de dialisis.
EP2691170A4 (en) BIN-FREE ZEOLITIC ADSORPTION AGENTS, METHOD FOR PRODUCING BINDER-FREE ZEOLITIC ADSORPTION AGENTS, AND ADSORPTIVE SEPARATION PROCESSES USING BINDING-FREE ZEOLITE ADSORPTION AGENTS
EA201270557A1 (ru) Способ очистки аденовируса из культур с высокой плотностью клеток
BR112014002251A2 (pt) pré-depurador de ar compacto versátil, método de depuração de ar, e, cartucho de filtro de ar descartável
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
PE20141386A1 (es) Sistemas de purificacion y mejoramiento del agua
WO2013028334A3 (en) Use of small molecules in methods for purification of biomolecules
BR112013025614A2 (pt) "métodos para purificação de hidrofobina ii e uso de um álcool para purificar a referida hidrofobina".
DE112012000715A5 (de) Verfahren zur Reinigung von Gasen oder Flüssigkeiten, Adsorbens dafür, Filter, sowie Verwendung des Adsorptionsmittels
BR112013029147A2 (pt) meio de filtração de líquidos, sistema de filtração para filtrar as partículas dos líquidos e processo para a produção de um meio de filtração de líquidos
MX2018003080A (es) Cartuchos utiles en soluciones de dialisis de limpieza.
MY188877A (en) Method to improve virus removal in protein purification
PL2286887T3 (pl) Usuwanie endotoksyn ze środków kontrastowych
NZ708503A (en) Purification of x-ray contrast agents
WO2013190453A3 (en) Compositions for separation methods

Legal Events

Date Code Title Description
FG Grant or registration